CONNECTING YOU TO BETTER HEALTH
Digital therapeutics for enhanced clinical outcomes
APPLICATION + MEDICATION
Digital application designed to enhance the efficacy of your medication.
Alex “Sandy” Pentland, PhD
Advisor on big data strategies
Alex “Sandy” Pentland has helped create and direct MIT’s Media Lab, the Media Lab Asia, and the Center for Future Health. He chairs the World Economic Forum’s Data Driven Development council, is Academic Director of the Data-Pop Alliance, and is a member of the Advisory Boards for Google, Nissan, Telefonica, the United Nations Secretary General, Monument Capital, and the Minerva Schools. In 2012 Forbes named Sandy one of the ‘seven most powerful data scientists in the world’, along with Google founders and the CTO of the United States, and in 2013 he won the McKinsey Award from Harvard Business Review. He is among the most-cited computational scientists in the world, and a pioneer in computational social science, organizational engineering, wearable computing (Google Glass), image understanding, and modern biometrics. His research has been featured in Nature, Science, and Harvard Business Review, as well as being the focus of TV features on BBC World, Discover and Science channels. His most recent book is `Social Physics,’ published by Penguin Press. Sandy’s research group and entrepreneurship program have spun off more than 30 companies to date, three of which are publicly listed and several that serve millions of poor in Africa and South Asia. Recent spin-offs have been featured in publications such as the Economist and the New York Times, as well as winning a variety of prizes from international development organizations.
Andrew J. Schwab
Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS (acquired by Fluidigm), Flexion (IPO), Ikaria (acquired by Madison Dearborn Partners), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.
Arjun Goyal, MD, MBA
Director of Corporate Development & Board Observer
Arjun has a background as a physician, entrepreneur and healthcare investor. He is an Associate at 5AM Ventures where he evaluates new investment opportunities and assists portfolio companies. Prior to joining 5AM Ventures, Arjun was co-founder of Foresight Pharmaceuticals, a company developing hormonal treatments for sexually transmitted infections. He trained in internal medicine through the University of Sydney hospital system and is the author of several patents. Earlier in his career, he served as an analyst in global health policy at the Australian Mission to the United Nations. He holds a B.S. in Medical Science, a Diploma in French and an M.D. from the Universities of Melbourne and Oxford, a M. Phil from the University of Cambridge and a MBA from Harvard Business School, where he was a Kaplan Life Science Fellow and an American Australian Association Fellow.
Chief Content Advisor
Beth is a media technology professional, transmedia producer and marketing strategist. She was a founding member of the internationally renowned Multimedia Studies Program at SFSU where she taught and published a book on multimedia. She then worked in hardware, software and services at such top firms as Silicon Graphics, Macromedia and the digital agency Circle, (bought by Euro RSCG). Beth has since founded games and apps companies including Signal 2 Productions, Match Factor and D2S Games. She helped produce and publish more than 30 casual games and apps, including apps for health care and wellness. Beth is an advisor to many start-ups including the Mobile Monday Momentum Accelerator, Grimm Bros Games, Major League Wizardry and Digify. In 2011, Beth founded Transmedia SF, an agency/studio/incubator/salon that boasts a community of over 5000 creatives and hosts regular educational and networking events.
William Greene, MD
Co-Founder and Medical
Bill has a background as a physician, healthcare investor and entrepreneur. He has been a Venture Partner at MPM Capital, were he has served on the Board of Directors at Intercell, Idun Pharmaceuticals, Barrier Therapeutics, Alnara, Cotherix, and most recently, Sai Advantium. He is also the current President and CEO of Iconic Therapeutics, a company developing novel therapeutics for ophthalmologic diseases. Prior to joining MPM, Bill was at Genentech where he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and regulatory affairs. He has also served at Yale Medical School, where he trained in Internal Medicine and Radiology, taught medicine, and conducted clinical research. He has been awarded the Henry Christian Award for outstanding research from the American Federation of Clinical Research and is a Member of the American College of Physicians. Dr. Greene holds an M.D. from UCSF, where he was an Assistant Professor of Medicine and a B.A., Phi Beta Kappa, from Wesleyan University.
VP of Commercialization
Christopher S. Lento is an experienced life sciences executive in the biotechnology & pharmaceutical fields. Mr. Lento has over 23 years of experience in senior leadership roles managing the commercial operations and new product launches at both start-up and established healthcare-focused companies including: Astra-Zeneca, Genentech BioOncology, US Oncology/McKesson, Abraxis Bioscience, ScribesSTAT, Altos Solutions and Galena Biopharma. Chris will be responsible for the US commercialization of Pear’s eFormualations. Chris received is BSBA, Finance from Providence College and his MBA, Marketing from Montclair State University.
Corey McCann, MD, PhD
Founder and Chief Executive Officer
Corey has background as a physician, scientist, entrepreneur, and healthcare investor. Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey’s Central Nervous System (CNS) expertise group, serving clients across pharma and biotech. He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain. Dr. McCann’s post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.
Director of Technical Operations
Daniel is passionate about Technical Operations and building robust, highly automated, secure infrastructures. Having moved to San Francisco in 2000 and caught the tail end of the dot com boom, over the years he has worked for several Bay Area startups. Prior to joining Pear he was working as a DevOps consultant, helping companies take advantage of the latest best practices and tooling to speed up their ability to deliver on their ideas.
Director of Customer Engagement
David Zuckerman brings a unique skill set to Pear Therapeutics. David began his career as a molecular biologist at the Dana-Farber Cancer Institute. After three years as a researcher in a pediatric oncology lab, he joined the Centers for Disease Control and Prevention (CDC) to help set up and run a bioterrorism lab. After building and running the lab for three years, David was looking for a new challenge and was recruited by a top performing investment team at Merrill Lynch. After 8 years in the investment field, David decided to join the Pear Therapeutics team to focus on operations. David received his BA in Biology from Skidmore College and is currently pursuing an MBA from Babson College.
Director of Product Development
Davina thrives on solving problems and finding creative, elegant ways to present complex information. With a background in engineering, technical communication, and fine art, she’s driven to discover the place where value, usability, and feasibility intersect. She excels in clarifying business requirements, stoking the fires of cross-functional teams, and leveraging lean methodologies to roll out successful products on time, regardless of constraints.
In 1998 Davina founded designwrench information arts, a small agency that provided print, identity, and web design and development to businesses and non-profits for over 15 years. In 2014, she joined forces with integrated design and development consultancy Cloud City as their Director of User Experience. While there, she played a key role in building content management systems and marketing websites for the Public Library of Science (PLOS), boosting the power and impact of Open Access scientific publishing.
When she’s not geeking out on process, Davina creates paintings, tapestries, sculptures, and installations inspired by her love of physics, nature, community, and connection.
Eliot is a full-stack engineer specializing in mobile front-end development. Before joining Pear, he worked for Disney Mobile and freelanced as an independent game developer. Eliot is excited to be part of the Pear team because it offers a unique opportunity to create innovative therapeutics powered by high quality, test-driven code.
Eric C. Leuthardt, MD
Advisor on Intellectual Property
Eric C. Leuthardt, M.D. is a neurosurgeon who is currently an associate professor with the Department of Neurological Surgery and the Department of Biomedical Engineering at Washington University in St. Louis. He is Director of the Center for Innovation in Neuroscience and Technology. He received his B.S. in Biology and Theology at St. Louis University in 1995 and received his M.D. at the University of Pennsylvania’s School of Medicine in 1999. He went on to complete his training at Barnes Jewish Hospital and Washington University in St. Louis in 2005 and then went on to pursue a combined fellowship in epilepsy and spinal surgery at the University of Washington in Seattle in 2006. His research has focused on neuroprosthetics – devices linked to the brain that may lead to cures for paralysis, allow patients to move artificial limbs, or restore other neurological functions. His work in the field of neuroprosthetics and neurosurgical devices has yielded him numerous accolades as a scientist, a neurosurgeon, and an inventor. Among other awards, Eric was named one of the Top Young Innovators by MIT’s magazine, Technology Review. In addition to the above, Eric was author of several of Pear’s core patents, covering clinical applications of eFormulations.
Eric is a recent graduate from Brandeis University who earned his B.A in Biology while minoring in Business. He has served as a research assistant at the Mount Sinai hospital, a histology lab technician at Robert Wood Johnson University, and a bioinformatics intern at New York University Langone Medical Center. He is published in the field of bioinformatics under Stuart Brown for helping create a draft genome of the coffee berry borer. Eventually developing a passion for business alongside healthcare, Eric has pursued administrative, marketing, and business development positions prior to joining Pear as an operations analyst. In the future, he plans to go back to business school in order to pursue his M.B.A.
Advisor on Child and Adolescent Psychiatry
Dr. Koplewicz is one of the nation’s leading child and adolescent psychiatrists. He is widely recognized as an innovator in the field, a strong advocate for child mental health, and a master clinician. He has been repeatedly recognized in America’s Top Doctors, Best Doctors in America, and New York Magazine’s Best Doctors in New York. Dr. Koplewicz is the President of the Child Mind Institute, the only independent non-profit organization exclusively dedicated to transforming mental healthcare for the world’s children. The Child Mind Institute is developing new and innovative treatments, building the science of healthy brain development and providing scientifically sound information about normal development, parenting and psychiatric disorders in children and adolescents an (childmind.org) to parents, educators and health professionals. Dr. Koplewicz has served as a member of the National Board of Medical Examiners and as a Commissioner of the New York State Commission on Youth, Crime and Violence and Reform of the Juvenile Justice System. Since 1997, Dr. Koplewicz has been the Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology. He was also a member of the working group organized by the U.S. Assistant Surgeon General and the U.S. Department of Health and Human Services to address the effects of terrorism on children’s mental health. Most recently he was selected to be a member of the mental health and disabilities working group of Vice President Joe Biden’s Task Force on Gun Violence. He has been at the forefront of public education to dispel the myths and stigma surrounding psychiatric disorders of children and adolescents. He has appeared regularly on national media and press discussing this topic.
Hilary Luderer, PhD
Director of Clinical Operations
Hilary is a scientist and writer. Her diverse scientific background includes bone and mineral biology, tissue repair and regeneration and inborn errors of metabolism. Prior to joining Pear, Hilary was an analyst in the Rare Genetic Diseases group at Agios Pharmaceuticals where she contributed to pipeline development, hypothesis generation and strategic planning. She has also worked as a scientific manuscript editor for American Journal Experts. Hilary holds a BS in Chemistry from the University of Michigan and a PhD in Cell and Molecular Biology from Washington University in St. Louis. Her postdoctoral training was at Massachusetts General Hospital and Harvard University.
Chief Technology Officer, General Manager
Ian is an entrepreneur and technologist. He’s the Founder and Chairman of Neo, a leading global product innovation company. He has a long track record of identifying trends early: he started working on worldwide distributed Hypertext systems in 1989 with Ted Nelson at Autodesk, about the same time Tim Berners-Lee started working on the World Wide Web. At Wired Magazine in 1994 he was on the launch team of HotWired, the first significant commercial Web application. There he worked with Brian Behlendorf on patches to NCSA HTTP, what would eventually become Apache, the basis of the Apache Software Foundation. In 1995 he met James Gosling at a demo of the new programming language Java, and subsequently built the first client server application ever written in Java, a technology demo for Sun’s announcement of the language at SunWorld. In 2004 he joined Friendster as employee number 3 and Chief Architect, the company that created the phenomenon we know today as Social Networking. In 2005 he joined Pivotal Labs, and as VP of Technology helped to build one of the most trusted brands in agile development consulting, and the first major consultancy to embrace Ruby on Rails. In 2009 he was part of the summit of design and technology leaders like Alan Cooper and Ward Cunningham that developed the integration of agile principals into design that would come to be known as Lean UX. In 2011, he left Pivotal Labs to join Digital Garage, a publicly traded Japanese company founded by Joi Ito, Director of the Media Lab at MIT, as Group CTO, and with the help of Eric Ries, author of the Lean Startup movement, to start building the consultancy he launched in 2012, Neo Innovation, Inc., of which he is Founder and Chairman. He’s helped to advise the White House Office of Science and Technology Policy and 18F, and has been a mentor and speaker at various accelerator programs, including 500 Startups, Tech Stars; Haxlr8r and Highway1 (Hardware accelerators, in Shenzhen, China, and San Francisco, respectively); and IndieBio (Sythetic Biology accelerator in San Francisco). He is an author and frequent speaker on Entrepreneurship, Lean, Agile, UX and Cloud.
Jason graduated from the University of Alberta, Canada with a B.Sc in Computer Engineering. Always looking for adventure, he’s worked in Canada, New Zealand, and Silicon Valley. He’s a believer in building lean and strives to find the balance between doing things right and doing things fast. Since joining Pear Therapeutics, Jason has helped shape the design and architecture of the software platform and pushed for better product and user experience.
Jeffrey A. Lieberman, MD
Advisor on Pharmacotherapies in Psychiatry
Jeffrey A. Lieberman, MD, is a physician and scientist who has spent his career of over 25 years caring for patients and studying the nature and treatment of mental illness. He is the Lawrence C. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as Psychiatrist in Chief at NewYork-Presbyterian Hospital – Columbia University Medical Center. Dr. Lieberman’s research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations and has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CATIE), sponsored by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.
Clinical Content Lead
Dr. Lipschitz is a licensed, clinical psychologist. She has eight years of experience in digital behavioral health, developing, evaluating, and implementing technology-based interventions in academic, government and industry settings. Her work has spanned a wide array of health concerns including depression, addiction, adherence, sleep, diet, exercise, anxiety, and self-management of chronic medical conditions.
Dr. Lipschitz maintains a clinical practice and an academic research program at the Boston VA Healthcare System/Harvard Medical School. Her research focuses on VA initiatives to improve eHealth options in new therapeutic areas and improve usability and implementation of existing technology-based behavioral health interventions. She is widely published and sits on the Association for Behavioral and Cognitive Therapies Continuing Education Committee. She is also a guest editor for the Journal of Internet Medical Research, Cognitive and Behavioral Practice, and Psychiatry Research.
Dr. Lipschitz completed her doctoral work at the University of Rhode Island under the mentorship of James Prochaska, a world leader in the field of technology-based behavioral health interventions and motivational tailoring. Her clinical internship was at the Boston VA Healthcare System/Harvard Medical School in General Mental Health. She earned her BA from Brown University.
JoAnn Difede, PhD
Advisor on Clinical Development
JoAnn Difede, Ph.D. is a Professor in the Department of Psychiatry at Weill Medical College of Cornell University, an Attending Psychologist at the New York-Presbyterian Hospital/Weill Cornell Medical Center, and Director of the Program for Anxiety and Traumatic Stress Studies (PATSS). She is internationally recognized for her pioneering work using virtual reality technology in the treatment of PTSD consequent to the WTC attack of September 11, 2001, and more recently in the treatment of combat-related PTSD. Dr. Difede is currently serving as the lead PI of a large multi-site Department of Defense funded clinical trial contract entitled, “Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with a Cognitive Enhancer,” which is investigating how the use of virtual reality and the pharmacologic agent, D-Cycloserine, may help accelerate recovery from combat-related PTSD among U.S. service members deployed to Iraq and Afghanistan. Dr. Difede has served as the PI of several NIH-funded treatment studies concerning the development of innovative treatments for PTSD. She received the 2010 Award for Outstanding Contributions to the Practice of Trauma Psychology from the American Psychological Association’s Division of Trauma. In addition to her scholarly endeavors, her work has been featured in many popular media venues including the New Yorker, the NY Times, Newsweek, the Washington Post, Scientific American, and many television programs, including a recent appearance on Charlie Rose: The Brain Series’ episode on PTSD, CNN, NBC, and ABC’s World News Tonight with Peter Jennings.
John is a General Partner at JAZZ Venture Partners and brings significant experience founding, funding and developing early-stage life sciences and technology companies. Prior to JAZZ, John was the founder, President and CEO of NeuroVista, a Seattle-based medical device company pioneering new technologies for the management and treatment of epilepsy. NeuroVista was acquired by Cyberonics in 2013 (NASDAQ: CYBX). John was also a founder and the Vice President of Marketing and Business Development at Northstar Neuroscience, which went public in 2006 (NASDAQ: NSTR) and was subsequently acquired by St. Jude Medial (NYSE: STJ). Prior to founding Northstar, he was a founder of Heartstream, a company that revolutionized the treatment of sudden cardiac arrest with uniquely designed external defibrillators that remain the market leader and can be found in airports, airplanes, stadiums, public buildings and many other locations. Heartstream went public in 1996, was subsequently acquired by Hewlett-Packard (NYSE: HPQ).
John holds a BS in industrial engineering from Stanford University and an MBA from Northwestern University’s Kellogg School of Management.
Katherine graduated from Boston University with a B.S. in Business Administration. She is a business analyst with a background in the retail and pharmacy industries. Katherine joined Pear after working on both the strategic initiatives team and the pricing & analytics team at CVS Health where she worked on a diverse range of projects including ones in digital healthcare and commercial strategy. She began her career working for several successful start-ups in the retail industry. Katherine is currently pursuing her master’s degree in Applied Business Analytics from Boston University.
Chief Commercial Advisor
Ken Andrews is an experienced health care executive across biotech, pharma and the software worlds. Ken brings general management, business development, marketing, sales, FDA and clinical development experience across a broad range of healthcare specialties including the opiate antagonist market. He is currently President and CEO of Endagon, and before that, President and CEO of Histogenics Corporation. Prior to this he led Alkermes introduction to the market with the partnering and launch of Vivitrol as Vice President of Marketing and Sales, and Chief Commercial Officer. Previously, he was founding CEO at Medicalis Corporation. Among his senior executive positions at biotechnology, pharmaceutical and device companies, he was Vice President of Marketing and Sales of the Tissue Repair Division of Genzyme Corporation and Vice President of U.S. Operations for Seikagaku Corporation, Tokyo Japan. He helped lead the creation of the initial sales and marketing organizations at both Genentech, Inc. and Centocor, Inc. Mr. Andrews graduated with a B.A. in marketing from the University of Tennessee.
Lisa Marsch, PhD
Advisor on Content Development
Lisa A. Marsch, PhD is the Director of the Center for Technology and Behavioral Health (CTBH), a “Center of Excellence” supported by the National Institute on Drug Abuse, focused on using science to inform the development, systematic evaluation, and sustainable implementation of digital therapeutic tools for substance use disorders and other areas of behavioral health. These tools leverage web, mobile, sensing, and/or social media approaches to deliver engaging and effective health behavior interventions and to collectively lead to transformations in the delivery of science-based health care. CTBH is housed at Dartmouth College but includes interdisciplinary partners across the U.S. and internationally. Dr. Marsch is also the Director of the Northeast Node of the National Drug Abuse Clinical Trials Network and the Andrew G. Wallace Professor within the Geisel School of Medicine at Dartmouth College.
Dr. Marsch has personally led many research initiatives on technology and behavioral health totaling over $50 million in grant funding, largely from the National Institutes of Health. Her work in technology and addiction treatment has been particularly pioneering, as she is widely recognized as having led the development of the most widely tested and evidence-based mobile intervention for addiction treatment.
Dr. Marsch publishes extensively and is a regular keynote speaker at national and international scientific meetings (including invited presentations at the White House, Congressional briefings, the World Bank, and for the US Surgeon General). She has served as a consultant to the Department of Mental Health and Substance Abuse at the World Health Organization. She serves on the National Advisory Council to the National Institute on Drug Abuse at the National Institutes of Health. She has also served on the Health Information Technology Policy Committee on Advanced Health Models and Meaningful Use for the U.S. Office of the National Coordinator.
Magali Haas, MD, PhD, MSE
Advisor on pharmaceutical industry partnerships
Dr. Haas is Founder and CEO of Orion Bionetworks, a nonprofit corporation dedicated to accelerating the discovery of next-generation diagnostics, treatments, and cures for brain disorders by harnessing the power of high-performance computing and data analytics to discover and develop predictive disease models from integrated biomarker, biosensor and phenotypic data. She also served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program. Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. As an “intrapreneur” at J&J she established the first Neuroscience Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as the first Healthcare Innovation team. She serves on several advisory boards including Brain Canada, the International Neuroinformatics Coordinating Facility, and IMEC for nano electronics and biosensors.
Matthew Smith, PhD
VP of Operations & Strategy
Matthew is a scientist, strategic consultant, and mental health advocate. He has held positions at Harvard Medical School and the University of Michigan over the last 7 years, making discoveries around how changes in the brain lead to mental disorders like Alzheimer’s disease and dementia. Matthew received his PhD in Neuropathology and this experience has left him acutely aware of the many hurdles in developing new pharmaceutical agents that can impact brain-related disease. As a consultant, Matthew has a diverse background analyzing the scientific rationale and economic opportunity of novel technologies in oncology, neurology, and anti-infectives, among others. Dr. Smith is a member of the American Association for the Advancement of Science, the American Chemical Society, the Alzheimer’s Association, and the Parkinson’s Action Network, all advocacy groups committed to improving patient outcomes through research.
VP of Regulatory Affairs
Ms. Murthy has over 20 years of work experience in regulatory affairs, clinical and quality assurance functions with multiple device specialties, including complex devices, such as Left Ventricular Assist Devices (LVADs) and Brain Computer Interface (BCI) devices. She has worked on novel mobile monitoring applications for cardiovascular, ECG and glucose monitoring, and is familiar with current regulatory requirements for such systems, including wireless and cybersecurity test requirements. She has authored numerous FDA submissions including original PMAs, original IDEs, Pre-Submissions, 510(k) submissions and De Novo filings. She has led projects where the technology or clinical application had no prior regulatory precedent, and developed strategy, led FDA communications and executed on complex submissions for the same. In addition to her core expertise in regulatory affairs, Ms. Murthy has designed and executed on clinical trials. She has also established quality systems to ISO 13485 and FDA Quality System requirements. . She has experience with product approvals for international markets such as EU (CE Mark), Japan and Canada. Ms. Murthy has served on the Management team of several companies, providing leadership to regulatory efforts, blending a strategic solution-oriented approach with strong tactical abilities. Ms. Murthy has a Masters in Science from UMass.
Chair of Advisory Board and Advisor on Healthcare Policy and Reimbursement.
Representative Patrick Kennedy served 16 years in the U.S. House of Representatives, and is predominantly known as author and lead sponsor of the Mental Health Parity and Addiction Equity Act of 2008. This dramatic piece of legislation provides tens of millions of Americans who were previously denied care with access to mental health treatment. Rep. Kennedy is now the co-founder of One Mind, a national coalition seeking new treatments and cures for neurologic and psychiatric diseases of the brain afflicting one in every three Americans. One Mind is dedicated to dramatic enhancements in funding and collaboration in research across all brain disorders in the next decade. Rep. Kennedy is also the founder of the Kennedy Forum on Community Mental Health which served as a vehicle to celebrate the 50th anniversary of President Kennedy’s signing of the Community Mental Health Act, the landmark bill that laid the foundation of contemporary mental health policy and provided Rep. Kennedy with the platform to launch a bold, ongoing effort to advance the work President Kennedy began. The Kennedy Forum continues to advocate for mental health parity.
Director of Software Quality Assurance and Compliance
Phu Trinh spent over 22 years building companies from start-up stage to successful M&A. His journey took him across companies in digital healthcare, eCommerce, eDiscovery, digital ticketing, medical devices and application provisioning. His highlights were Relsys’ Argus Safety (acquired by Oracle in 2009), Clearwell’s eDiscovery Platform (acquired by Symantec in 2011) and CenterRun’s application provisioning (acquired by Sun Microsystems – now Oracle in 2003). As a co-founder of Relsys, Phu helped grow the company from 5 employees to over 40 employees. Relsys was recognized as the Deloitte 50 Fastest Growing Company in Orange County, California. Phu has experience in product management, software development, quality assurance, project management, implementation services and FDA compliance. Phu holds a Bachelor of Science in Electrical Computer Engineering from California State Polytechnic University, Pomona.
Sarmad is a software and technology enthusiast. He started programming as a hobby when he was 12 years old, and he spent more than 15 years in professional software development across various industries including games, desktop tools, and web development. With experience in dozens of software technologies and programming languages, his knowledge of computer technologies spans the entire stack from low level programming to high level systems and architectures. He has written code for Honda, Nokia, Microsoft, and few other companies during his career, and he has targeted mobile devices, desktops, web browsers, as well as backend and database servers. He is the author of Alusus programming language, an open-source multi-purpose programming language that he designed in his spare time in a hope to make the programming landscape simpler and more efficient for the new generations of programmers. Sarmad also spends his spare time writing articles and blog posts about software development. When it comes to coding habits, he strives for simplicity as well as proper software design principles, but he tries to balance those with efficient coding. Sarmad has a B.Sc. in computer engineering.
Stephen Kennedy Smith, JD
Co-founder and EVP of Corporate Development
Stephen is an entrepreneur, business advisor, and has a long career in the development, funding and expansion of companies. He has served as a director or advisor to several companies, including Gridline Communications Holdings, RAPID Pharmaceuticals, Mainland Resources and, Med-Design Corp. Stephen is also an active member of the Kennedy family financial advisory board. He served as Deputy Campaign Manager for Senator Edward Kennedy during his presidential and senatorial campaigns, and also served on the staff of the Senate Judiciary and Foreign Relations Committees. Stephen taught negotiation at Harvard University Law School and is a three-time winner of Harvard’s Danforth Award for Excellence in Teaching and a recipient of the Lyndehurst Foundation prize for social and artistic achievement. Mr. Kennedy-Smith holds an M.A. from Harvard University, a J.D. from Columbia University, and an M.A. Ed. from Harvard’s School for Education.
Tim Petersen joined Arboretum Ventures as a Managing Director in 2002.
Tim’s investment focus has been shaped by his broad business experience with creating, growing, and financing entrepreneurial firms. His investments primarily target capital-efficient companies in medical technology, health IT and services that redefine efficient models for care delivery and improve access to care. Tim has led investments and held board seats in more than a dozen portfolio companies during his tenure with Arboretum. Tim led Arboretum’s investment into health IT company HealthMedia, which was acquired by J&J in 2008. He also led Arboretum’s investment into Accuri Cytometers, which was acquired by BD in 2011 for $205 million and Inogen, which went public in 2014. An innovator in the delivery of oxygen to patients with COPD, Inogen’s market capitalization exceeded one billion in 2015.
From 1999 to 2002, he helped establish the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan, serving as its Managing Director. The Institute has been consistently ranked as one of the top three entrepreneurship programs in the country. During his tenure at Michigan, he also directed the activities of the Wolverine Venture Fund, the Institute’s venture capital fund focusing on early-stage life science and technology investments. Prior to Michigan, Tim was a manager in the investment banking practice at Plante Moran Corporate Finance and served as a management consultant at Industrial Economics, Inc. in Cambridge, MA
Tom Shehab, MD
Tom Shehab, M.D., joined Arboretum Ventures in 2014 as a Principal.
Previously, Tom served as a member of Arboretum’s Technical Advisory Board and as a board member of an Arboretum portfolio company, ArborMetrix. In his current role, Tom draws upon his clinical, healthcare administration and operational expertise to evaluate new potential investments and provide strategic support to Arboretum’s portfolio companies.
Prior to joining Arboretum, Tom spent 12 years as a physician executive and practicing physician specializing in gastroenterology. He was involved in a number of entrepreneurial healthcare related ventures and held multiple senior leadership roles. Most recently, Tom served as Chief of Staff for more than 1,000 physicians at St. Joseph Mercy Hospital in Ann Arbor and as the Chair of Medicine for Integrated Health Associates (IHA), a multi-specialty group consisting of 300+ providers. Both St. Joseph Mercy Hospital and IHA are part of Trinity Health.
Senior Software QA Engineer
Tony is motivated by the prospect to help deliver high quality Prescription Digital Therapies in Pear’s pipeline. Having worked as contributor as well as QA lead at Netscape/AOL, RedHat, Affinity Circles, Linden Lab, and Covia Lab, he has well rounded experience in QA methodology, automation, load and performance testing against backend servers, social networking sites, games, web and mobile applications. Tony holds a Computer Science degree from UC Berkeley.
Walter Greenleaf, PhD
Chief Science Officer
Walter has a background in both neuroscience research and clinical product development. As a research scientist, Dr. Greenleaf has focused on age-related changes in the human neuroendocrine system, and the effects of hormones on mood and behavior. His PhD is in Neuro- and Bio-Behavioral Sciences, from Stanford University. His most recent academic appointment was as Director for the Mind Division, Stanford Center on Longevity. As a medical product developer, Walter has designed and developed several clinical product streams: his focus has been on the use of simulation and telemedicine technology to treat difficult problems in behavioral and physical medicine. Dr. Greenleaf founded and served as CEO for: Greenleaf Medical Systems, a business incubator; InWorld Solutions, specializing in the therapeutic use of virtual worlds for behavioral health care; and Virtually Better, which develops virtual environments for the treatment of phobias, anxiety disorders, and PTSD.
Yuri Maricich, MD, MBA
VP of Clinical Development
Dr. Maricich is a licensed, board-certified physician, investor, and strategist. He works to improve our healthcare system by investing in, advising for, and leading innovative firms. He has worked with & led successful healthcare & life science (HLS) firms including Xdynia (acquired by Cavion), Corixa (acquired by GlaxoSmithKline) and maintains active patient care practice. He founded a digital health firm as a 3rd year medical student that focused on data-structuring of clinical documents using NLP. He has worked with & advised a diversity of HLS technology and investment firms. These include a leading cloud computing firm, digital health, biotech, healthcare, device, and IP law. He invests in public and private firms and raised funds. Current focus includes Big Data, analytics, therapeutics, diagnostics, genomics, delivery, digital health, value-driven care, services & mobile health. Dr. Maricich was in Michael Porter’s first Value-Driven Health Care course at Harvard. As a 2nd year medical student he founded the Pathos Project. He is a published author and frequent speaker. Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, his M.B.A. from Harvard Business School, and his undergraduate at the University of Notre Dame, with studies in pre-professional science and philosophy. He completed internal medicine training at the University of Virginia Health System.
Zack Lynch is General Partner at JAZZ Venture Partners.
Zack is an entrepreneur, market maven and futurist who brings a rich understanding of the technologies and companies driving the experiential technology market to JAZZ. He is the founder and chairman of the Neurotechnology Industry Organization (NIO), a global trade association of over 120 companies involved in developing treatments for neurological diseases, psychiatric illnesses and nervous system injuries. He is the founder and curator of the Experiential Technology and NeuroGaming Conference and Expo which is the leading meeting bringing together tech executives, game designers, neuroscientists and investors focused on improving human performance. He is the author of the best-selling book, The Neuro Revolution: How Brain Science Is Changing our World published by St. Martin’s Press.
5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors. We support companies solving important healthcare needs via cutting-edge breakthroughs in medicine and science. Our portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions.
5AM’s investment professionals possess strong scientific, medical, operational, legal and finance expertise. Our complementary backgrounds provide us with a unique edge to find and shape life science portfolio companies. Our team employs a time-tested, hands-on approach to company building and, in addition to being an early investor and contributing as board members, 5AM is often directly involved in setting company strategy, management recruiting, business development and fundraising, and we frequently take on short-term operating roles.
Arboretum Ventures is a venture capital firm specializing in the healthcare sector. Founded in 2002, the firm manages $450 million in capital and has invested in more than 35 companies. Headquartered in Ann Arbor, Arboretum invests throughout the United States, but with a preference for Midwest opportunities. Our team targets capital efficient companies that can meaningfully reduce healthcare costs in our areas of expertise: devices, diagnostics, services, and IT. We are actively seeking new investments for Arboretum Ventures IV, a $220 million fund raised in 2015.
JAZZ Venture Partners invests in companies developing experiential technology that improves human performance. At the intersection of digital consumer platforms, such as virtual and augmented reality, and neuroscience, these companies are impacting health, mind-body wellness, peak mental and physical acuity, accelerated learning and training, sports, and entertainment.
Our mission is to fund and support the visions of social entrepreneurs who have scalable business models for applications, practices, products and tools that build bridges for mind-training and its impact on their lives. We see a world where those who imagine deeper, richer connections with themselves and others are offered practical paths to achieve meaningful growth in their lives.
We seek to demystify contemplative practices and illuminate their potential by offering applications and tools that build bridges for all to experiential discoveries about inner self and outer meaning and action.